Treatment Advances

July 15, 2024

TCR-T Therapies TSC-100 and TSC-101 were given FDA Designation in AML, ALL, and MDS.

June 18, 2024

Cancer vaccines are a promising area of medical research for MDS, aimed at enabling the immune system to target and destroy cancer cells.

June 12, 2024

Imetelstat reduces blood transfusions and improves hemoglobin levels. Learn how this drug works and its safety profile.

May 20, 2024

Dr. Amy DeZern shared how the medicine tamibarotene is helping high-risk MDS and AML patients with an overexpressed RARA gene in their cancer cells.

April 24, 2024

Discover elritercept: Fast Track FDA designation for MDS anemia treatment. Innovative therapy targeting blood cell production pathways.

March 28, 2024

Imetelstat received a positive FDA committee vote for treating transfusion-dependent anemia in LR-MDS. Learn about potential benefits for MDS patients.

March 11, 2024

Bexmarilimab is showing promise in clinical trials as an effective treatment option for MDS patients

February 19, 2024

Disease outcome is extremely important, but no individual should have to go into bankruptcy because of their cancer treatment costs. 

November 08, 2023

Learn about Bemcentinib, a new treatment being tested as an option For High Risk MDS and AML

October 03, 2023

Immunosuppressive therapy can be an option for patients with lower-risk MDS (LR-MDS). A common type of immunotherapy for MDS is antithymocyte globulin (ATG).